1. INNOVATION
IN THE DEVELOPMENT OF NEW DRUGS AND CREATIVE SOLUTIONS TO ENSURING EARLY AND ENHANCED ACCESS
Paul Stoffels, M.D. Chief Scientific Officer, Johnson & Johnson

2. HIV LIFE EXPECTANCY

3. HIV TODAY The Opportunity: The Challenges:
More than 20 Antiretroviral Drugs and Combinations
Diagnostics : CD4, Viral Load, Resistance Testing
The Challenges:
Life Long Therapy (30-50 years)
Highly mutable virus leading to resistance
Supply Chain
Logistics
Funding

4. WHAT IS NEEDED: INNOVATION
Innovation in Therapy
Innovation in Prevention
Innovation in Implementation

5. HIV protease gene diversity matrix
Viral isolates
SQV viruses 1 10 20 30 40 50 60 70 80 90
Amino-acid position

6. INNOVATION IN THERAPY New Drug Targets – Existing Drug Targets
Combinations
Single pill
New Regimens
Strategically Designed Regimens
Efficacy
Prevent resistance
Implementation and cost
Long Acting Formulations
Treatment Strategies
Treat to prevent
Combating resistance

7. INNOVATION IN PREVENTION
Barrier Prevention
Chemical Prevention
PrEP
Vaginal Ring
Long-Acting Injectables
Biological Prevention
Antibodies
HIV Vaccine—The Holy Grail

8. – FOR 50 YEARS
Strategically deploy the drugs we have for maximal life expectancy and optimal access
Green Pill First—Red Pill Next
Universal Viral Load Testing
Avoid MDR HIV

9. INNOVATION IN ACCESS
Stratification and Simplification of Drug Regimens
Supply
Logistics
Deployment
Cost

10. ACCELERATING INNOVATION FOR IMPACT
Transfer Best Practices
Drug development focused on
Accelerate drug / vaccine developments:
Oncology : 24 months
Vaccines : Ebola vaccine – 18 months
Every day counts

12. 30 Million people X 50 years = 1.5 billion years of life.